Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome.
Wong F, Pappas SC, Curry MP, Reddy KR, Rubin RA, Porayko MK, Gonzalez SA, Mumtaz K, Lim N, Simonetto DA, Sharma P, Sanyal AJ, Mayo MJ, Frederick RT, Escalante S, Jamil K; CONFIRM Study Investigators.
N Engl J Med. 2021 Mar 4;384(9):818-828. doi: 10.1056/NEJMoa2008290.
PMID:33657294
News in pathophysiology, definition and classification of hepatorenal syndrome: A step beyond the International Club of Ascites (ICA) consensus document.
Evidence-based clinical practice guidelines for Liver Cirrhosis 2020.
Yoshiji H, Nagoshi S, Akahane T, Asaoka Y, Ueno Y, Ogawa K, Kawaguchi T, Kurosaki M, Sakaida I, Shimizu M, Taniai M, Terai S, Nishikawa H, Hiasa Y, Hidaka H, Miwa H, Chayama K, Enomoto N, Shimosegawa T, Takehara T, Koike K.
World J Gastroenterol. 2012 Sep 28;18(36):4978-84. doi: 10.3748/wjg.v18.i36.4978.
PMID:23049205
Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome: A randomized controlled study.
Cavallin M, Piano S, Romano A, Fasolato S, Frigo AC, Benetti G, Gola E, Morando F, Stanco M, Rosi S, Sticca A, Cillo U, Angeli P.
Hepatology. 2016 Mar;63(3):983-92. doi: 10.1002/hep.28396. Epub 2016 Feb 3.
PMID:26659927
Treating Hepatorenal Syndrome in the Current Era.
Velez JCQ.
J Am Soc Nephrol. 2026 Feb 1;37(2):370-381. doi: 10.1681/ASN.0000000920. Epub 2025 Oct 22.